Company intelligence / Profile preview
CYTLIMIC
Shinagawa City, Tokyo, Japancytlimic.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CYTLIMIC develops novel immunotherapy products, primarily therapeutic peptide vaccines for cancer. Its lead candidate, CYT001, targets liver cancer and has advanced to Phase II clinical trials. The company leverages proprietary AI technology from NEC to rapidly discover and optimize new vaccine candidates tailored to genetic profiles common in Japan. Early results show promise for safety and efficacy in activating anti-tumor immune responses.
- Therapeutic areas
- Oncology
- Modalities
- Peptide vaccinesImmunostimulantsBiological products
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NEC CorporationYamaguchi UniversityKochi UniversityFast Track Initiative Inc.SMBC Venture Capital Co., Ltd.NEC Capital Solutions LimitedPrima Biomed
Beyond the preview
Go deeper on CYTLIMIC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYTLIMIC.